ABOUT
TECHNOLOGY
Overview
Mechanism of Action
Pipeline
ADPKD
PATIENTS
INVESTORS
Overview
Press Releases
Events and Presentations
Financials & Filings
SEC Filings
Quarterly Results
Corporate Governance
Governance Documents
Board of Directors
Committee Composition
Analyst Coverage
Stock Information
Historical Stock Price
Investment Calculator
Insider Transactions
Fundamentals
Form 8937
Investor FAQs
Contact Us
CAREER
Toggle nav
Press Releases
.
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Investor Alerts
Year
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
May 06, 2024
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
April 30, 2024
Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series
March 21, 2024
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
March 12, 2024
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
March 12, 2024
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
64
»
